AstraZeneca will have 200 million COVID-19 antibody dosages by year-end Kumar Jeetendra | November 23, 2020 AstraZeneca will have enough of its own candidate vaccine for 200 million doses by the end of 2020, with drug substance for 700 million doses by the end of the first quarter of 2021 worldwide, operations executive Pam Cheng said on Monday. Cheng told a briefing that the company would keep the”active” drug substance in …
Unilever says its mouthwash will decrease 99.9% Covid in the wake of flushing Kumar Jeetendra | November 21, 2020 International FMCG major Unilever on November 21 said it will bring to India its mouthwash formulation, which, it claims, will reduce 99.9 percent of coronavirus after 30 minutes of rinsing. “Unilever has confirmed that preliminary lab test results reveal that mouthwash formulation containing CPC Technology reduces 99.9 percent of SARS-CoV-2, the virus which causes COVID-19, …
Asahi Kasei Pharma Contracts ProBioGen for the Advancement of their Biologics Pipeline Kumar Jeetendra | November 18, 2020 BERLIN, Germany, November 18, 2020 / B3C newswire / — ProBioGen AG announced the closing of a master service agreement with Asahi Kasei Pharma. As an expert CDMO in high-titer cell line development till large scale GMP manufacturing, ProBioGen will use its proprietary technologies, like the CHO.RiGHT® cell line development platform and DirectedLuck™ transposase technology, …
J&J expects information for US approval of COVID-19 antibody by February, says head researcher Kumar Jeetendra | November 18, 2020 Johnson & Johnson’s chief scientist said the drugmaker is recruiting over 1,000 people per day for the late-stage trial of its experimental COVID-19 vaccine and hopes to have all the data required to seek U.S. authorization by February or earlier. “From the end of the year or around the end of the year, we should …
Cipla launches “Covi-G” for COVID-19 rapid antibody detection Kumar Jeetendra | November 18, 2020 Mumbai, November 18, 2020: Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as “Cipla”) today announced that it signed a licensing agreement with a Belgium-based firm, Multi G for the distribution of their COVID-19 Rapid Antibody test kit, across most Emerging markets and Europe. This licencing agreement is part of Cipla’s efforts …
Dose-escalation study to evaluate safety, biological and early clinical effect of CALY-002 in healthy volunteers and patients with Celiac Disease and Eosinophilic Esophagitis Kumar Jeetendra | November 16, 2020 AMSTERDAM, The Netherlands, November 16, 2020 Calypso Biotech, a company developing Interleukin-15-targeted biologics, today announced completion of dosing of first cohort of healthy subjects in the first Phase 1 clinical trial of CALY-002, a novel humanized monoclonal antibody neutralizing IL-15. “CALY-002 is the lead program of our differentiated pipeline of IL-15-targeting biologics, that we plan …
Lead Pharma Enters into a Research Collaboration and License Agreement with Roche Kumar Jeetendra | November 16, 2020 OSS, The Netherlands, November 16, 2020 Lead Pharma, a clinical stage pharmaceutical company, designing and developing innovative medicines for the treatment of immune mediated diseases and cancer, today announced that it has entered into a collaboration and license agreement with Roche to develop oral small molecules to treat a broad range of immune mediated diseases. …
Johnson and Johnson, US government extend settlement to help next phase of COVID-19 immunization R&D Kumar Jeetendra | November 15, 2020 Johnson & Johnson and the US Department of Health and Human Services have expanded an agreement to support the next phase of COVID-19 vaccine candidate research and development, the company said on Saturday. Under the agreement the company will commit approximately $604 million and the HHS Department’s Biomedical Advanced Research and Development Authority will commit …
Pill Connect secures £0.5m to take electronic smart pill bottle that monitors patient adherence to commercial launch Kumar Jeetendra | November 14, 2020 Pill Connect, formerly known as Elucid mHealth, has completed a £510,000 funding round with the support of the serial entrepreneur Jonathan Milner, Catapult Ventures and Shallcross Partners. The capital raised will enable Pill Connect to complete development of the design, electronics and software for submission to the regulatory authorities in both Europe and the US …
Lupin, Concord Biotech get USFDA gesture for generic immunosuppressant cases Kumar Jeetendra | November 12, 2020 New Delhi, Nov 12 (PTI) Drug firm Lupin on Thursday stated that in alliance with Concord Biotech, it has obtained acceptance from the US health regulator to market generic immunosuppressant Tacrolimus capsules used in the Western industry. In cooperation with Concord Biotech, the business has obtained approval from the United States Food and Drug Administration …
Glenmark Pharma gets USFDA gesture for Tacrolimus capsules Kumar Jeetendra | November 11, 2020 Tacrolimus capsule is an immunosuppressant and can be employed for preventing organ rejection in certain patients after kidney, liver, or heart transplant. Glenmark Pharmaceuticals Inc, USA, has been granted final approval by the United States Food and Drug Administration (USFDA) for Tacrolimus Capsules USP in the strengths of 0.5 mg, 1 mg and 5 mg, …
Repositive expands global cancer model network with CRO from Finland Kumar Jeetendra | November 10, 2020 CAMBRIDGE, UK – (November 10, 2020) – Life Science Newswire – Repositive, the world’s largest directory of preclinical cancer models, has expanded its global network of contract research organisation (CRO) partners with the addition of Pharmatest, a CRO providing clinically predictive preclinical efficacy services for oncology and skeletal diseases. Pharmatest brings to the partnership more …
